Report on the annual accounts of the European Medicines Agency for the financial year 2013, together with the Agency’s reply 2014/C 442/22
Grade B
mapped from publisher markup. A grade says how a document's structure was obtained, not how reliable the law is.
Not the law itself: Notice
Address https://gelex.eu/eli/EU/notice/oj/C/2014/442/22@2014-07-01/en
The European Medicines Agency (hereinafter the Agency, aka EMA), which is located in London, was established by Council Regulation (EEC) No 2309/93, which was replaced by Regulation (EC) No 726/2004 of the European Parliament and of the Council. The Agency operates through a network and coordinates the scientific resources made available by the national authorities in order to ensure the evaluation and supervision of medicinal products for human or veterinary use. The audit approach taken by the Court comprises analytical audit procedures, direct testing of transactions and an assessment of key controls of the Agency’s supervisory and control systems. This is supplemented by evidence provided by the work of other auditors (where relevant) and an analysis of management representations. Pursuant to the provisions of Article 287 of the Treaty on the Functioning of the European Union (TFEU), the Court has audited:
(a) the annual accounts of the Agency, which comprise the financial statements and the reports on the implementation of the budget for the financial year ended 31 December 2013, and
(b) the legality and regularity of the transactions underlying those accounts.
The management is responsible for the preparation and fair presentation of the annual accounts of the Agency and the legality and regularity of the underlying transactions:
(a) The management’s responsibilities in respect of the Agency's annual accounts include designing, implementing and maintaining an internal control system relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error; selecting and applying appropriate accounting policies on the basis of the accounting rules adopted by the Commission’s accounting officer; making accounting estimates that are reasonable in the circumstances. The Director approves the annual accounts of the Agency after its accounting officer has prepared them on the basis of all available information and established a note to accompany the accounts in which he declares, inter alia, that he has reasonable assurance that they present a true and fair view of the financial position of the Agency in all material respects.
(b) The management’s responsibilities in respect of the legality and regularity of the underlying transactions and compliance with the principle of sound financial management consist of designing, implementing and maintaining an effective and efficient internal control system comprising adequate supervision and appropriate measures to prevent irregularities and fraud and, if necessary, legal proceedings to recover funds wrongly paid or used.
The Court’s responsibility is, on the basis of its audit, to provide the European Parliament and the Council with a statement of assurance as to the reliability of the annual accounts and the legality and regularity of the underlying transactions. The Court conducts its audit in accordance with the IFAC International Standards on Auditing and Codes of Ethics and the INTOSAI International Standards of Supreme Audit Institutions. These standards require the Court to plan and perform the audit to obtain reasonable assurance as to whether the annual accounts of the Agency are free from material misstatement and the transactions underlying them are legal and regular. The audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the accounts and the legality and regularity of the underlying transactions. The procedures selected depend on the auditor’s judgement, which is based on an assessment of the risks of material misstatement of the accounts and material non-compliance by the underlying transactions with the requirements in the legal framework of the European Union, whether due to fraud or error. In assessing these risks, the auditor considers any internal controls relevant to the preparation and fair presentation of the accounts, as well as the supervisory and control systems that are implemented to ensure the legality and regularity of underlying transactions, and designs audit procedures that are appropriate in the circumstances. The audit also entails evaluating the appropriateness of accounting policies, the reasonableness of accounting estimates and the overall presentation of the accounts. The Court considers that the audit evidence obtained is sufficient and appropriate to provide a basis for its statement of assurance. In the Court’s opinion, the Agency’s annual accounts present fairly, in all material respects, its financial position as at 31 December 2013 and the results of its operations and its cash flows for the year then ended, in accordance with the provisions of its Financial Regulation and the accounting rules adopted by the Commission’s accounting officer. In the Court’s opinion, the transactions underlying the annual accounts for the year ended 31 December 2013 are legal and regular in all material respects. The comments which follow do not call the Court’s opinions into question. An overview of the corrective actions taken in response to the Court's comments from previous years is provided in Annex I. This Report was adopted by Chamber IV, headed by Mr Milan Martin CVIKL, Member of the Court of Auditors, in Luxembourg at its meeting of 1 July 2014. For the Court of Auditors Vítor Manuel da Silva Caldeira President
ANNEX
ANNEX I Follow-up of previous years’ comments
Year Court's comment Status of corrective action (Completed/Ongoing/Outstanding/N/A) 2011 There is scope for improving the transparency of procurement procedures. Completed 2011 The Court identified a need to improve the transparency of staff selection procedures. Selection Board members did not always complete their conflict of interest declarations, or did not do so in a timely manner, and there was no evidence of any action taken to address the issues raised by these declarations. The documentation of the Selection Board’s proceedings was not always adequate and there is no evidence as to how the method for the short-listing of candidates was established and that the questions for the written tests or interviews were set before the examinations. Completed 2012 The Agency applies differing recognition criteria for fee revenue and associated expenditure. Revenue from application fees is recognised on a straight-line basis over a set time period. Expenditure for the evaluation of such applications by the competent national authorities is however accrued when a specific milestone in service delivery is reached. This is in contradiction with the matching principle. Completed 2012 The Agency has not yet validated its accounting system in the area of intangible fixed assets. Given the considerable investment in the ICT development, this is a crucial part of the whole accounting system. Completed 2012 In 2011 and 2012, the Council refused salary increases for EU staff. The Commission appealed this decision to the Court of Justice which did not yet rule on the matter. Since the Agency is located in London, the salary increases in question will be paid in GBP whereas the Agency’s accounts are prepared in Euros. Given the fluctuations in the exchange rate over the period concerned, the possible back pay to staff would lead to an estimated exchange rate loss for the Agency of 2,9 million euro. The Agency has included this amount in the calculation of its budgetary outturn account, leading to an equivalent understatement of funds to be paid back to the Commission. N/A 2012 In 2012, the Agency issued cascading framework contracts for the provision of services. The procurement procedure presented some irregularities affecting the principle of transparency. N/A 2012 In addition to the education allowances provided for in the Staff Regulations, the Agency pays education contributions directly to schools for staff whose children attend primary or secondary school without having contracts with schools in place. Total 2012 education contributions amounted to some 389 000 euro. Such expenditure is not covered by the Staff Regulations and irregular. Ongoing 2012 The Agency’s budget implementation rates for the year 2012 were satisfactory for titles I and III. While the rate of committed appropriations carried over was high for title II at 27 %, this primarily relates to the Agency’s planned move to new premises in 2014 (4 205 000 euro) and the development of ICT systems (1 596 000 euro). While the latter is of a multiannual nature that can partly justify the carry-overs, the Agency’s ICT Unit was significantly reorganised in 2012 and a number of projects planned for 2012 were delayed. N/A
ANNEX II European Medicines Agency (London) Competences and activities
Source: Annex supplied by the Agency. Areas of Union competence deriving from the Treaty (Article 168 of the Treaty on the Functioning of the European Union) Collection of information A high level of human health protection shall be ensured in the definition and implementation of all Union policies and activities. Union action, which shall complement national policies, shall be directed towards improving public health, preventing physical and mental illness and diseases, and obviating sources of danger to physical and mental health. Such action shall cover the fight against the major health scourges, by promoting research into their causes, their transmission and their prevention, as well as health information and education, and monitoring, early warning of and combating serious cross-border threats to health. Competences of the Agency (Regulation (EC) No 726/2004 of the European Parliament and of the Council) Objectives Tasks Governance The Committee for Medicinal Products for Human Use (CHMP) is responsible for preparing the Agency's opinions on all questions concerning medicines for human use. The CHMP consists of one member and one alternate from each Member State, one member and an alternate nominated by Iceland and by Norway and up to five co-opted members. The Committee for Medicinal Products for Veterinary Use (CVMP) is responsible for preparing the Agency's opinions on all questions concerning veterinary medicines. The CVMP consists of one member and one alternate from each Member State, Iceland and Norway and up to five co-opted members. The Committee on Orphan Medicinal Products (COMP) is responsible for reviewing applications from people or companies seeking orphan medicinal product designation. The COMP consists of one member from each Member State, three members nominated by the European Commission representing patients’ organisations, three members nominated by the European Commission on the Agency’s recommendation, one member nominated by Iceland, one by Liechtenstein and one by Norway, and one European Commission representative. The Committee on Herbal Medicinal Products (HMPC) is responsible for preparing the Agency’s opinions on herbal medicines. The HMPC consists of one member and one alternate from each Member State, Iceland and Norway, and up to five co-opted members. The Paediatric Committee (PDCO) is responsible for assessing the content of applications: for paediatric investigation plans, with or without request of deferral(s) and/or partial waivers; for modification of a previously agreed paediatric investigation plan; for product-specific waivers and for compliance checks. The PDCO consists of five members of the CHMP and their five alternates, one member and one alternate from each Member State which is not represented by the five above, and six members and alternates appointed by the European Commission representing healthcare professionals and patients’ associations. The Committee for Advanced Therapy (CAT) is responsible for assessing the quality, safety and efficacy of advanced therapy medicinal products (ATMPs) and following scientific developments in the field. The CAT consists of five members of the CHMP and their five alternates, one member and one alternate from each Member State which is not represented by the five above, and four members and four alternates appointed by the European Commission representing patients’ associations and clinicians. The Pharmacovigilance Risk Assessment Committee (PRAC) is responsible for assessing and monitoring safety issues for human medicines. The PRAC consists of one member and one alternate from each Member State, Iceland and Norway, six independent scientific experts nominated by the European Commission and two members and two alternates nominated by the European Commission to represent healthcare professionals and patients’ organisations The Management Board consists of one member and one alternate from each Member State, two representatives of the Commission, two representatives of the European Parliament and two representatives from patients' organisations, one representative from doctors' organisations and one representative from veterinarians' organisations. The Board adopts the work programme and the annual report. The Executive Director is appointed by the Management Board on a proposal from the Commission. Internal audit Commission’s Internal Audit Service (IAS) EMA Internal Audit Capability (IAC) External audit European Court of Auditors Discharge authority European Parliament, acting on a recommendation from the Council Resources made available to the Agency in 2013 (2012) Final Budget 251,560 (222,489) million euro; Union contribution: 13,0 % (9,6 %) Staff as at 31 December 2013 611 (590) in the establishment plan, of which occupied: 583 (575) 144 (160) other staff (contract staff, seconded national experts, employment agency staff) Total staff: 727 (735), undertaking the following tasks: operational: 590 (594), administrative 137 (141) Products and services in 2013 (2012) Medicinal Products for Human Use Medicinal Products for Veterinary Use Inspections Inspections: 480 (450) Herbal Medicinal Products Herbal monographs: 9 (15) List of herbal substances, preparations and combinations thereof: 0 (0) Orphan Medicinal Products SMEs
To coordinate the scientific resources that the Member States’ authorities make available to the Agency for the authorisation and supervision of medicinal products for human and veterinary use,
to provide the Member States and the institutions of the European Union with scientific advice on medicinal products for human or veterinary use.
To coordinate the scientific evaluation of medicinal products which are subject to Union marketing authorisation procedures,
to coordinate the supervision of medicinal products which have been authorised within the Union (Pharmacovigilance),
to advise on the maximum limits for residues of veterinary medicinal products which may be accepted in foodstuffs of animal origin,
to coordinate verification of compliance with the principles of good manufacturing practice, good laboratory practice and good clinical practice,
to record the status of marketing authorisations granted for medicinal products.
Applications for marketing authorisations: 80 (96)
Favourable opinions: 80 (57)
Average evaluation time: 200 (188) days
Opinions after authorisation: 5 447 (5 137)
Pharmacovigilance (CAP EEA and non-EEA ADR reports): 679 413 (522 073) reports
Periodic safety update reports: 525 (463)
Scientific advice finalised: 474 (420)
Mutual Recognition Procedures and Decentralised Procedures: started 6 293 (6 991); ended 6 242 (6 709)
Applications for paediatric investigation plans: 211 (178) relating to 225 (218) indications
Applications for marketing authorisations: 23 (13)
Applications in respect of variants: 315 (261)
Applications: 201 (197)
Favourable opinions: 136 (139)
Requests for SME status 401 (684)
Applications for fee reduction or deferrals 336 (316)
THE AGENCY’S REPLY
The European Medicines Agency has taken note of the Court of Auditors’ report.